ArticleThe Journal of infectious diseases2026
Molecular and Serological Evidence of Oropouche Virus Circulation in Asymptomatic Blood Donors During the 2023-2024 Outbreak in Manaus, Brazil.
Article in The Journal of infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrated surveillance resolves Darién paradox of Oropouche virus emergence in Panama's migration corridor.Research square · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundOropouche virus (OROV) re-emerged in Brazil in 2023, causing over 26 000 confirmed cases through December 2025. A reassortant lineage was linked to neurologic complications and congenital infections due to vertical transmission. Although transfusion transmission has not been reported, asymptomatic viremia in blood donors could represent an unrecognized route of infection.
methodsWe conducted nucleic acid testing (NAT), genomic, and serological surveillance among blood donors in Manaus, Brazil, during the 2023-2024 OROV outbreak. Minipools (MPs) of 18 donations from November 2023 to May 2024 were tested using a validated RT-qPCR assay. A subset of NAT-reactive pools underwent whole genome sequencing and phylogenetic analysis. Serosurveys in November 2023 and June 2024 assessed changes in population immunity. The RNA-detectable window was estimated by integrating NAT yield with seroincidence.
resultsAmong 661 MPs, representing 11 898 donations, 43 (6.5%) were OROV RNA-reactive, peaking in January 2024. About half contained viral RNA concentrations above the limit of quantification. Donor-derived viral genomes clustered with the reassortant lineage circulating in Brazil. Donor seropositivity increased from 13.0% to 29.7%, corresponding to approximately 390 000 estimated infections in Manaus, substantially higher than reported case numbers. The estimated MP RNA-detectable window was 5.4 days (95% CI: 3.8-7.0).
conclusionsOROV RNA detection in donor samples, together with high-titer viremia, phylogenetic identity to the outbreak strain, and postoutbreak seroconversion, raises questions about blood safety. Continued donor and recipient surveillance will be vital to determine transfusion-transmission risk and inform transfusion safety policies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.